Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

Neuroscience Letters

Volumn 355, Issue 3, 2004, Pages 169-172

  Am, Orit Bar ^a   Amit, Tamar ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Aminoindan; L Methamphetamine; MAO, monoamine oxidase; Neuroprotection; Neurotoxicity rasagiline; Parkinson's disease; PD, Parkinson's disease; PKC MAP kinase pathway; Selegiline

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AMINOIDAN; ANTIPARKINSON AGENT; APOPTOSIS INHIBITOR; DRUG METABOLITE; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; NERVE GROWTH FACTOR; PROTEIN KINASE C; RASAGILINE; SELEGILINE; TVP136; UNCLASSIFIED DRUG; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT;

ANALYTIC METHOD; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TIME; ANIMAL; CELL DEATH; CELL STRAIN; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; CELL DEATH; INDANS; NEUROPROTECTIVE AGENTS; PC12 CELLS; RATS; SELEGILINE;

EID: 1542317394     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2003.10.067     Document Type: Article

References (20)

1. Abu-Raya S., Tabakman R., Blaugrund E., Trembovler V., Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur. J. Pharmacol. 434:2002;109-116.
2. Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto-Nagai M., Youdim M.B.H., Tsujimoto Y., Naoi M. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82:2002;913-923.
3. Birkmayer W., Riederer P., Ambrozi L., Youdim M.B.H. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1:1977;439-443.
4. Finberg J.P., Lamensdorf I., Weinstock M., Schwartz M., Youdim M.B.H. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv. Neurol. 80:1999;495-499.
5. Finberg J., Youdim M.B.H. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 43:2002;1110-1118.
6. Gassen M., Lamensdorf I., Armony T., Finberg J.P., Youdim M.B. Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation. J. Neural Transm. 110:2003;171-182.
7. Maruyama W., Akao Y., Youdim M.B.H., Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm. 60:(Suppl.):2000;171- 186.
8. Maruyama W., Weinstock M., Youdim M.B., Nagai M., Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl] -ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. 341:2003;233-236.
9. Oh C., Murray B., Bhattacharya N., Holland D., Tatton W.G. (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J. Neurosci. Res. 38:1994;64-74.
10. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. Arch. Neurol. 59:2002;1937-1993.
11. Pellegrini-Giampietro D.E., Peruginelli F., Meli E., Cozzi A., Albani-Torregrossa S., Pellicciari R., Moroni F. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms. Neuropharmacology. 38:1999;1607-1619.
12. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., Marler J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 60:2003;1234-1240.
13. Reynolds G.P., Riederer P., Sandler M., Jellinger K., Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J. Neural Transm. 43:1978;271-277.
14. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol anti-oxidative therapy of Parkinsonism. Ann. Neurol. 44:1998;S160-S166.
15. Speiser Z., Mayk A., Eliash S., Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J. Neural Transm. 106:1999;593-606.
16. Yogev-Falach M., Amit T., Bar-Am O., Youdim M.B.H. The importance of propargylamine moiety in the anti-Parkinson drug, rasagiline and its derivatives for MAPK dependent amyloid precursor protein processing. FASEB J. 17:2003;. (in press).
17. Youdim M.B.H., Amit T., Yogev-Falach M., Bar-Am O., Maruyama W., Naoi M. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-anti-apoptotic action of the anti-Parkinson drug, rasagiline. Biochem. Pharmacol. 66:2003;1635-1641.
18. Youdim M.B.H., Heldman E., Pollard H.B., Fleming P., McHugh E. Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC12 and chromaffin cells. Neuroscience. 19:1986;1311-1318.
19. Youdim M.B.H., Wadia A., Tatton N.A., Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. N. Y. Acad. Sci. 939:2001;450-458.
20. Youdim M.B.H., Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug, TV3326, [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell. Mol. Neurobiol. 21:2002;555-573.